Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Psychiatric disorders are common and account for a growing share of global morbidity, with depression and anxiety responsible for roughly half of this burden. Existing treatments—psychotherapy and pharmacotherapy—are generally effective but many patients remain treatment-resistant, creating demand for new approaches. Recent regulatory attention and industry activity have focused on treatments that intentionally combine psychoactive compounds with structured psychotherapy, such as psilocybin-assisted psychotherapy and MDMA-assisted psychotherapy, alongside developments like intranasal esketamine for treatment-resistant depression. The terminology around these agents varies: classical psychedelics (e.g. LSD, psilocybin) are typically 5HT2A agonists, MDMA is often described as an entactogen or empathogen, and ketamine as a dissociative; all can induce temporary, profound alterations of consciousness that may be harnessed therapeutically. Greenway and colleagues set out to review the principles, history, mechanisms, and clinical results of psychedelic-assisted psychotherapy (PAP), with emphasis on LSD and psilocybin. The review also places PAP in the broader context of conventional psychotherapy and antidepressant pharmacology, aiming to clarify shared and distinct mechanisms whereby combined psychotherapeutic and pharmacological treatments may produce benefit.

The investigators performed a narrative review based on two Medline/PubMed searches restricted to English-language records before 1 January 2020. The search terms were 'psychedelic*' (yielding 1,038 results) and 'antidepressant AND psychotherapy AND review AND (depression OR mood)' (2,122 results). ClinicalTrials.gov was also queried for completed trials of psilocybin, LSD, MDMA, and ketamine. Publications identified in those searches were screened for relevance, and additional articles were retrieved iteratively from the reference lists of key reviews and trials. In total, approximately 239 publications were selected for inclusion in the review. As a narrative review, the paper synthesises historical, mechanistic, and clinical literature rather than conducting a formal meta-analysis. The authors draw on clinical trials, observational studies, mechanistic neuroimaging and neurobiological work, and earlier descriptive literature to compare conventional and psychedelic paradigms and to describe common factors that may mediate therapeutic effects.

The review summarises evidence across several domains, beginning with conventional treatments. Combining psychotherapy and pharmacotherapy is established as a gold standard for many psychiatric disorders; antidepressants (from monoamine oxidase inhibitors through SSRIs and SNRIs) are widely prescribed and effective for many patients but have limitations including delayed onset, side effects that can persist after discontinuation, about 50% poor adherence, and debate about magnitude and durability of benefit. Population prescribing has increased substantially (an estimated 1 in 8 American adults had filled an antidepressant prescription in 2013). Psychotherapies such as cognitive behavioural therapy (CBT) exhibit comparable efficacy to antidepressants for many depressive disorders and tend to yield more persistent post-treatment benefits. The authors highlight the contextual model of psychotherapy, which emphasises three common factors—therapeutic relationship, expectation/meaning-making, and enactment of health-promoting actions—and note that many benefits of disparate psychotherapies may be mediated by such shared processes. A central theme is shared and interactional mechanisms when drugs and psychotherapy are combined. Antidepressant effects appear not solely explicable by a simple monoamine-correction model; contemporary explanations emphasise neuroplasticity, inflammation, and glutamatergic systems and suggest that pharmacotherapy may increase sensitivity to environmental input. Placebo effects in depression trials are large, with placebos achieving 50% to 85% of antidepressant levels of efficacy in some studies, and the therapeutic context, explanatory models, and the quality of the therapeutic alliance materially influence outcomes. Re-analyses of large trials (for example STAR*D) and animal studies suggest that antidepressant dosing may amplify responsiveness to positive or negative environments, a potential mechanism for interaction with psychotherapy. Historically, early psychedelic research (primarily with LSD) influenced psychiatric thinking by challenging prevailing explanatory models and by foregrounding the importance of interpersonal context. Modern psychedelics (LSD, psilocybin, DMT, mescaline) share potent 5HT2A agonism as a core pharmacodynamic feature. Typical psychotropic dosing parameters cited include LSD 100–200 μg with effects lasting about 8–12 hours and peaking near 2 hours, psilocybin with a shorter duration of roughly 4–6 hours, and rapid tachyphylaxis (tolerance) after consecutive dosing—commonly attributed to 5HT2A receptor desensitisation. Psychedelic phenomenology routinely includes perceptual changes, increased suggestibility, feelings of ego dissolution or oceanic boundlessness, and experiences that participants often rate as highly meaningful. Neuroimaging studies report decreased segregation within canonical networks and increased cross-network communication, with attention paid to disintegration of the Default Mode Network correlating with subjective ego-dissolution; these network-level changes have been framed in models invoking reduced top-down constraint or increased entropy of brain dynamics. MDMA and ketamine are pharmacologically distinct from classical psychedelics but share therapeutic applications. MDMA reverses monoamine transporters leading to increased presynaptic serotonin, norepinephrine and dopamine, and secondary hormonal changes (including oxytocin release) that promote prosociality; standard research doses are around 75–125 mg with effects lasting roughly 4 hours. From 2004–2016, six Phase II MDMA-assisted psychotherapy trials conducted under MAPS reported substantial PTSD symptom improvements and acceptable tolerability; the FDA awarded Breakthrough Therapy designation to MDMA-assisted psychotherapy in 2017 and Phase III trials began in late 2018, with an Expanded Access program planned. Ketamine is primarily an NMDA antagonist that produces rapid antidepressant effects—improvements sometimes occurring within hours of a single subanaesthetic dose—consistent with its putative action on neuroplasticity. Typical clinical infusion protocols cited include 0.5 mg/kg IV administered over 40 minutes, two to three times weekly for maintenance in many programmes, though higher and lower doses have been used; ketamine has been used in both biomedical paradigms (where dissociative effects are treated as side-effects) and in PAP-like models where experiential aspects are integrated therapeutically. Regarding clinical outcomes from PAP studies, modern psilocybin trials report rapid and often large effect sizes across indications such as treatment-resistant depression, end-of-life anxiety, and smoking cessation, with benefits in many studies persisting from 6 months to nearly 5 years in follow-up. MDMA trials in PTSD have shown durable symptom reductions in Phase II work. Adverse events in structured PAP trials are reported to be comparable to standard psychotherapy when appropriate safeguards (screening, preparation, two therapists per session, attention to set and setting, and integration) are used; however, recreational use in uncontrolled environments has led to injuries and deaths, typically in the context of polysubstance use or hazardous settings. The reviewed literature identifies low addiction potential for classic psychedelics, though MDMA has moderate recreational abuse liability and ketamine carries a higher risk for misuse and physiological dependence. Key non-pharmacological components associated with outcomes include rigorous patient selection and preparation, optimising set and setting (therapeutic milieu, music), supported drug sessions with guides, and post-session integration therapy.

Greenway and colleagues interpret the literature as pointing to a convergent, integrative framework in which psychotherapy and psychopharmacology interact bidirectionally rather than acting in separable additive ways. They argue that the contextual model of psychotherapy (relationship, expectation/meaning, and enactment) maps well onto key aspects of psychedelic-assisted approaches, and that increased environmental sensitivity produced by pharmacological agents may partly explain enhanced responsiveness to psychotherapeutic processes. In PAP specifically, acute amplifications of mental processes can yield rapid, large, and sometimes durable therapeutic gains—advantages that may be particularly important in treatment-resistant populations. The authors emphasise both opportunities and challenges. Potential advantages include ultra-rapid benefit for responders, reduced need for ongoing daily medications, clearer clinical pictures following remission, and therapeutic narratives that may increase patient autonomy. Challenges highlighted include careful patient selection and the need for medication adjustments that carry risks (for example, discontinuation phenomena or serotonin syndrome), the necessity of optimising set and setting and ensuring safety during profound altered states, and uncertainty about whether trial-level standards and experienced therapist effects will translate to routine clinical settings. Implementation barriers include stigma, resource intensity (long sessions, two therapists), and structural changes required in healthcare delivery. Several research priorities are identified: conducting comparative studies against a wider array of treatments and psychotherapies (including component analyses), optimising dosing regimens and numbers/timing of psychedelic sessions, characterising the psychotherapeutic mechanisms most important for specific molecules and populations, ensuring demographic diversity in samples, and pursuing longer-term follow-up studies to establish maintenance strategies. The authors also call for continued mechanistic work to elucidate neural processes underlying psychedelic, MDMA, and ketamine effects. They note limitations of the current evidence base, including that much research has been performed by experienced, motivated therapists within tightly controlled trials, which may limit generalisability to community settings.